Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone

被引：0
|
作者：
Mathews, Maju [1 ]
Pei, Huiling [1 ]
Savitz, Adam [1 ]
Nuamah, Isaac [1 ]
Elefant, Erica [1 ]
Hough, David [1 ]
Alphs, Larry [1 ]
Gopal, Srihari [1 ]
机构：
[1] Janssen Res & Dev, Titusville, NJ USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM409
引用
收藏
页码：197 / 198
页数：2
相关论文
共 50 条
  • [21] “Real world” clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients
    Vincent Ferraro
    Simon Lafrenière
    Marie-France Demers
    Marc-André Roy
    Amal Abdel-Baki
    Psychopharmacology, 2020, 237 : 3795 - 3797
  • [22] BUDGET IMPACT ANALYSIS OF PALIPERIDONE PALMITATE 3-MONTHLY FOR THE TREATMENT OF SCHIZOPHRENIA IN ITALY
    Povero, M.
    Pradelli, L.
    VALUE IN HEALTH, 2017, 20 (09) : A710 - A710
  • [23] Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study
    Savitz, A.
    Gopal, S.
    Xu, H.
    Zhuo, J.
    Yu, L.
    Nuamah, I.
    Wu, C.
    Hough, D.
    Mathews, M.
    Feng, Y.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 201 - 201
  • [24] Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
    Brasso, Claudio
    Bellino, Silvio
    Bozzatello, Paola
    Montemagni, Cristiana
    Rocca, Paola
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 2767 - 2779
  • [25] Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
    Charmi Patel
    Bruno Emond
    Marie-Hélène Lafeuille
    Aurélie Côté-Sergent
    Patrick Lefebvre
    Neeta Tandon
    Antoine C. El Khoury
    Drugs - Real World Outcomes, 2020, 7 : 19 - 29
  • [26] Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
    Patel, Charmi
    Emond, Bruno
    Lafeuille, Marie-Helene
    Cote-Sergent, Aurelie
    Lefebvre, Patrick
    Tandon, Neeta
    El Khoury, Antoine C.
    DRUGS-REAL WORLD OUTCOMES, 2020, 7 (01) : 19 - 29
  • [27] Clinical effectiveness of paliperidone palmitate intramuscular 3-monthly formulation in patients with schizophrenia: A case series
    Porras Segovia, A.
    Guerrero, M.
    Carrillo de Albornoz, C.
    Gutierrez-Rojas, L.
    EUROPEAN PSYCHIATRY, 2018, 48 : S533 - S533
  • [28] SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING
    Garcia-Portilla, M. P.
    Llorca, P. M.
    Maina, G.
    Bozikas, V. P.
    Devrimci-Ozguven, H.
    Kim, S. W.
    Bergmans, P.
    Usankova, I.
    Cherubin, P.
    Najarian, Dean
    Pungor, K.
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S295 - S296
  • [29] PALIPERIDONE PALMITATE 3-MONTHLY COMPARED WITH 1-MONTHLY FORMULATION IN PATIENTS WITH SCHIZOPHRENIA: GLOBAL AND ASIAN SUBPOPULATION ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY STUDY
    Savitz, A.
    Gopal, S.
    Feng, Y.
    Xu, H.
    Zhuo, J.
    Yu, L.
    Nuomah, I.
    Ravenstijn, P.
    Wu, C.
    Hough, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2016, 50 : 166 - 167
  • [30] Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
    Lopez, Alicia
    Rey, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 449 - 456
12345